Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.42 |
| ▸ | HTR2A | P28223 | 1/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.42 |
| ▸ | HRH1 | P35367 | 1/20 | 0.42 |
| ▸ | HTR2B | P41595 | 1/20 | 0.42 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.40 |
| ▸ | ESR1 | P03372 | 1/20 | 0.40 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.40 |
| ▸ | GABBR2 | O75899 | 3/20 | 0.39 |
| ▸ | GABBR1 | Q9UBS5 | 3/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL684422 | 1.00 | BRD4 (0.47) | BRD4SLC6A2HTR2ASLC6A4HRH1 | |
| SCHEMBL684738 | 1.00 | BRD4 (0.47) | BRD4SLC6A2HTR2ASLC6A4HRH1 | |
| SCHEMBL12167835 | 0.87 | SLC6A2 (0.42) | BRD4SLC6A2HTR2ASLC6A4HRH1 | |
| SCHEMBL10122759 | 0.87 | SLC6A2 (0.42) | BRD4SLC6A2HTR2ASLC6A4HRH1 | |
| SCHEMBL680823 | 0.84 | POLB (0.42) | BRD4SLC6A2HTR2ASLC6A4HRH1 | |
| SCHEMBL680865 | 0.84 | POLB (0.42) | BRD4SLC6A2HTR2ASLC6A4HRH1 | |
| SCHEMBL679766 | 0.84 | POLB (0.42) | BRD4SLC6A2HTR2ASLC6A4HRH1 | |
| SCHEMBL12323381 | 0.83 | SLC6A2 (0.42) | BRD4SLC6A2HTR2ASLC6A4HRH1 | |
| SCHEMBL684740 | 0.83 | AOC3 (0.40) | AOC3ESR1ESR2GABBR2GABBR1 | |
| SCHEMBL681802 | 0.81 | SLC6A2 (0.40) | BRD4SLC6A2HTR2ASLC6A4HRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160235754-A1 | HYDROXYLATED AND METHOXYLATED PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2016-08-18 | — | — | US | disclosed |
| US-9359340-B2 | Hydroxylated and methoxylated pyrimidyl cyclopentanes as Akt protein kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2016-06-07 | — | — | US | disclosed |
| US-20160152606-A9 | HYDROXYLATED AND METHOXYLATED PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | GENENTECH, INC. | 2016-06-02 | — | — | US | disclosed |
| US-9303040-B2 | Substituted piperazines as AKT inhibitors | ARRAY BIOPHARMA INC. (US) | 2016-04-05 | — | — | US | disclosed |
| EP-2966065-A2 | HYDROXYLATED AND METHOXYLATED CYCLOPENTA [D] PYRIMIDINES AS AKT PROTEIN KINASE INHIBITORS | Array Biopharma, Inc. (US) | 2016-01-13 | — | — | EP | disclosed |
| EP-2402325-B1 | Hydroxylated cyclopenta[d]pyrimidines as AKT protein kinase inhibitors | ARRAY BIOPHARMA INC (US) | 2015-08-26 | — | — | EP | disclosed |
| EP-2399909-B1 | Hydroxylated cyclopenta[d]pyrimidines as AKT protein kinase inhibitors | ARRAY BIOPHARMA INC (US) | 2015-08-26 | — | — | EP | disclosed |
| US-20150191479-A1 | DIHYDROFURO PYRIMIDINES AS AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA, INC. | 2015-07-09 | — | — | US | disclosed |
| US-20140349997-A1 | HYDROXYLATED AND METHOXYLATED PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2014-11-27 | — | — | US | disclosed |
| US-20140349996-A1 | PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2014-11-27 | — | — | US | disclosed |
| EP-2399909-A1 | Hydroxylated and methoxylated cyclopenta[d]pyrimidines as akt protein kinase inhibitors | Array Biopharma, Inc. (US) | 2011-12-28 | — | — | EP | disclosed |
| US-8063050-B2 | Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2011-11-22 | — | — | US | disclosed |
| US-20110269773-A1 | DIHYDROFURO PYRIMIDINES AS AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA, INC. | 2011-11-03 | — | — | US | disclosed |
| US-20110245230-A1 | PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2011-10-06 | — | — | US | disclosed |
| US-8003651-B2 | Pyrimidyl cyclopentanes as AKT protein kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2011-08-23 | — | — | US | disclosed |
| EP-2049546-B1 | DIHYDROFURO PYRIMIDINES AS AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2010-12-29 | — | — | EP | disclosed |
| US-20080058327-A1 | 4-piperazinyl-5H-6,7-dihydrocyclopenta(d)pyrimidines; Hyperproliferative diseases such as cancer | GENENTECH, INC. | 2008-03-06 | — | — | US | disclosed |
| US-20080051399-A1 | HYDROXYLATED AND METHOXYLATED PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2008-02-28 | — | — | US | disclosed |
| WO-2008006040-A1 | HYDROXYLATED AND METHOXYLATED CYCLOPENTA [D] PYRIMIDINES AS AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2008-01-10 | — | — | WO | disclosed |
| WO-2008006032-A1 | CYCLOPENTA [D] PYRIMIDINES AS AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2008-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080058327-A1 | 4-piperazinyl-5H-6,7-dihydrocyclopenta(d)pyrimidines; Hyperproliferative diseases such as cancer | PIK3CA, DPYD, CDK2 | BRD4 1810/4885SLC6A2 2330/4885HTR2A 1693/4885 |
| US-20160235754-A1 | HYDROXYLATED AND METHOXYLATED PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | AKT1, AKT2, AKT3 | BRD4 2427/4885SLC6A2 3273/4885HTR2A 1812/4885 |
| US-20080051399-A1 | HYDROXYLATED AND METHOXYLATED PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | AKT1, AKT2, AKT1S1 | BRD4 2369/4885SLC6A2 3153/4885HTR2A 1733/4885 |
| US-20110269773-A1 | DIHYDROFURO PYRIMIDINES AS AKT PROTEIN KINASE INHIBITORS | DPYD, PIK3CA, DTYMK | BRD4 1963/4885SLC6A2 4080/4885HTR2A 3647/4885 |
| US-20140349997-A1 | HYDROXYLATED AND METHOXYLATED PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | AKT1, AKT2, AKT1S1 | BRD4 2369/4885SLC6A2 3153/4885HTR2A 1733/4885 |
| US-20150191479-A1 | DIHYDROFURO PYRIMIDINES AS AKT PROTEIN KINASE INHIBITORS | DPYD, DTYMK, PIK3CA | BRD4 1861/4885SLC6A2 4011/4885HTR2A 3511/4885 |
| US-20160152606-A9 | HYDROXYLATED AND METHOXYLATED PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | AKT1, AKT2, AKT1S1 | BRD4 2369/4885SLC6A2 3153/4885HTR2A 1733/4885 |
| US-20140349996-A1 | PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | TK1, PIK3CA, AKT1 | BRD4 3681/4885SLC6A2 2079/4885HTR2A 2758/4885 |
| US-20110245230-A1 | PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | TK1, PIK3CA, AKT1 | BRD4 3681/4885SLC6A2 2079/4885HTR2A 2758/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.